Peter T. W. Cheng

2.6k total citations · 1 hit paper
49 papers, 1.5k citations indexed

About

Peter T. W. Cheng is a scholar working on Molecular Biology, Organic Chemistry and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Peter T. W. Cheng has authored 49 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Molecular Biology, 21 papers in Organic Chemistry and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Peter T. W. Cheng's work include Peroxisome Proliferator-Activated Receptors (10 papers), Catalytic C–H Functionalization Methods (9 papers) and Catalytic Cross-Coupling Reactions (5 papers). Peter T. W. Cheng is often cited by papers focused on Peroxisome Proliferator-Activated Receptors (10 papers), Catalytic C–H Functionalization Methods (9 papers) and Catalytic Cross-Coupling Reactions (5 papers). Peter T. W. Cheng collaborates with scholars based in United States, Canada and Sweden. Peter T. W. Cheng's co-authors include Jin‐Quan Yu, William R. Ewing, Jun Shi, Jennifer X. Qiao, Kap‐Sun Yeung, Shiwei Tao, Michael A. Poss, Peng Wang, Pritha Verma and Hao Zhang and has published in prestigious journals such as Nature, Science and Journal of the American Chemical Society.

In The Last Decade

Peter T. W. Cheng

49 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ligand-accelerated non-directed C–H functionalization of arenes

2017 341 citations Peng Wang, Pritha Verma et al. Nature profile →

Peers

Countries citing papers authored by Peter T. W. Cheng

Since Specialization

Citations

This map shows the geographic impact of Peter T. W. Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter T. W. Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter T. W. Cheng more than expected).

Fields of papers citing papers by Peter T. W. Cheng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter T. W. Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter T. W. Cheng. The network helps show where Peter T. W. Cheng may publish in the future.

Co-authorship network of co-authors of Peter T. W. Cheng

This figure shows the co-authorship network connecting the top 25 collaborators of Peter T. W. Cheng. A scholar is included among the top collaborators of Peter T. W. Cheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter T. W. Cheng. Peter T. W. Cheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Alkene Difunctionalization Directed by Free Amines: Diamine Synthesis via Nickel-Catalyzed 1,2-Carboamination 2022 ·ACS Catalysis ·Taeho Kang, (unknown), Zi‐Qi Li, Klement Foo, Peter T. W. Cheng, Keary M. Engle	46
2	Mechanism of hepatobiliary toxicity of the LPA1 antagonist BMS-986020 developed to treat idiopathic pulmonary fibrosis: Contrasts with BMS-986234 and BMS-986278 2022 ·Toxicology and Applied Pharmacology ·Michael Gill, Brian J. Murphy, Peter T. W. Cheng, Lakshmi Sivaraman, (unknown), Lois D. Lehman‐McKeeman	18
3	Structural and Thermal Characterization of Halogenated Azidopyridines: Under-Reported Synthons for Medicinal Chemistry 2021 ·Organic Letters ·Michael D. Mandler, Andrew P. Degnan, Shasha Zhang, Darpandeep Aulakh, (unknown), Bhupinder Sandhu, Amy A. Sarjeant, Yeheng Zhu, Sarah C. Traeger, Peter T. W. Cheng, Bruce A. Ellsworth, Alicia Regueiro‐Ren	8
4	BMS-986278, an LPA ₁ Receptor Antagonist for Idiopathic Pulmonary Fibrosis: Preclinical Assessments of Potential Hepatobiliary Toxicity 2019 ·Michael Gill, (unknown), Peter T. W. Cheng, B.J. Murphy, (unknown), Lois D. Lehman‐McKeeman, Michael J. Graziano	5
5	Selective C−H Halogenation with a Highly Fluorinated Manganese Porphyrin 2017 ·Angewandte Chemie International Edition ·Gang Li, Andrew K. Dilger, Peter T. W. Cheng, William R. Ewing, John T. Groves	82
6	Selective C−H Halogenation with a Highly Fluorinated Manganese Porphyrin 2017 ·Angewandte Chemie ·Gang Li, Andrew K. Dilger, Peter T. W. Cheng, William R. Ewing, John T. Groves	18
7	Ligand-accelerated non-directed C–H functionalization of arenes breakdown → 2017 ·Nature ·Peng Wang, Pritha Verma, Guoqin Xia, Jun Shi, Jennifer X. Qiao, Shiwei Tao, Peter T. W. Cheng, Michael A. Poss, Marcus E. Farmer, Kap‐Sun Yeung, Jin‐Quan Yu	341
8	Characterization of RON protein isoforms in pancreatic cancer: implications for biology and therapeutics 2016 ·Oncotarget ·Jeffery Chakedis, Randall P. French, Michele Babicky, Dawn Jaquish, Evangeline Mose, Peter T. W. Cheng, (unknown), (unknown), (unknown), (unknown), (unknown), Carsten Schultz‐Fademrecht, Christina Esdar, Oliver Schadt, Jan Eickhoff, Andrew M. Lowy	24
9	Ligand‐Promoted Borylation of C(sp³)H Bonds with Palladium(II) Catalysts 2015 ·Angewandte Chemie International Edition ·Jian He, Heng Jiang, Ryosuke Takise, Ru‐Yi Zhu, Gang Chen, Hui‐Xiong Dai, T. G. Murali Dhar, Jun Shi, Hao Zhang, Peter T. W. Cheng, Jin‐Quan Yu	126
10	Plasma Stability-Dependent Circulation of Acyl Glucuronide Metabolites in Humans: How Circulating Metabolite Profiles of Muraglitazar and Peliglitazar Can Lead to Misleading Risk Assessment 2010 ·Drug Metabolism and Disposition ·Donglu Zhang, Nirmala Raghavan, Lifei Wang, Yongjun Xue, Mary T. Obermeier, Stephanie Chen, Shiwei Tao, Hao Zhang, Peter T. W. Cheng, Wenying Li, Ragu Ramanathan, Yang Zheng, W. Griffith Humphreys	22
11	Metabolism and Disposition of 14C-Labeled Peliglitazar in Humans 2010 ·Drug Metabolism and Disposition ·Lifei Wang, (unknown), Sean Chen, Samuel J. Bonacorsi, Peter T. W. Cheng, W. Griffith Humphreys, Donglu Zhang	15
12	Genetic and gene expression studies implicate renin and endothelin-1 in edema caused by peroxisome proliferator-activated receptor γ agonists 2008 ·Pharmacogenetics and Genomics ·William J. Geese, William E. Achanzar, Cindy J. Rubin, Narayanan Hariharan, Peter T. W. Cheng, Lindsay Tomlinson, (unknown), Nicholas C. Dracopoli, Terrye Delmonte, Lester Hui, Bala Krishnan, Greg Cosma, Koustubh Ranade	11
13	Design, synthesis, and structure–activity relationships of piperidine and dehydropiperidine carboxylic acids as novel, potent dual PPARα/γ agonists 2008 ·Bioorganic & Medicinal Chemistry Letters ·Xiang‐Yang Ye, Yixin Li, Dennis Farrelly, Neil Flynn, Li‐Qun Gu, (unknown), Jonathan Lippy, Kevin O’Malley, (unknown), Litao Zhang, Denis E. Ryono, Robert Zahler, Narayanan Hariharan, Peter T. W. Cheng	6
14	A rapid, homogeneous, fluorescence polarization binding assay for peroxisome proliferator-activated receptors alpha and gamma using a fluorescein-tagged dual PPARα/γ activator 2007 ·Analytical Biochemistry ·Ramakrishna Seethala, Rajasree Golla, Zhengping Ma, Hao Zhang, K O'Malley, Jonathan Lippy, Lin Cheng, Kasim A. Mookhtiar, Dennis Farrelly, Litao Zhang, Narayanan Hariharan, Peter T. W. Cheng	13
15	Discovery of tertiary aminoacids as dual PPARα/γ agonists-I 2007 ·Bioorganic & Medicinal Chemistry Letters ·Pratik Devasthale, Sean Chen, Yoon Jeon, (unknown), Denis E. Ryono, Wei Wang, Hao Zhang, Lin Cheng, Dennis Farrelly, Rajasree Golla, Gary J. Grover, Zhengping Ma, (unknown), Ramakrishna Seethala, Wei Sun, Arthur M. Doweyko, Gamini Chandrasena, Paul G. Sleph, Narayanan Hariharan, Peter T. W. Cheng	7
16	Discovery, synthesis, and structure–activity studies of tetrazole based growth hormone secretagogues 2007 ·Bioorganic & Medicinal Chemistry Letters ·Andrés S. Hernández, Peter T. W. Cheng, (unknown), (unknown), R.J. George, Gary J. Grover, (unknown), Ramakrishna Seethala, Mark A. Smith, Kenneth E.J. Dickinson, (unknown), Daniel Angelo Longhi, Neil Flynn, Brian J. Murphy, David A. Gordon, Scott A. Biller, Jeffrey A. Robl, Joseph A. Tino	22
17	Mass Defect Filtering on High Resolution LC/MS Data as a Methodology for Detecting Metabolites with Unpredictable Structures: Identification of Oxazole-Ring Opened Metabolites of Muraglitazar 2007 ·Drug Metabolism Letters ·Donglu Zhang, Peter T. W. Cheng, Haiying Zhang	11
18	Pharmacokinetics of muraglitazar (BMS-298585), a dual peroxisome proliferator-activated receptors (PPAR) α and γ activator, in mice, rats, dogs, and monkeys 2006 ·Xenobiotica ·Vinayak Hosagrahara, Gamini Chandrasena, Sang‐Yoon Chang, Barry Koplowitz, Narayanan Hariharan, Peter T. W. Cheng, W. Griffith Humphreys	3
19	Comparative Metabolism of Radiolabeled Muraglitazar in Animals and Humans by Quantitative and Qualitative Metabolite Profiling 2006 ·Drug Metabolism and Disposition ·Donglu Zhang, Lifei Wang, Nirmala Raghavan, Haiying Zhang, Wenying Li, Peter T. W. Cheng, Ming Yao, Litao Zhang, Mingshe Zhu, Samuel J. Bonacorsi, Suresh Yeola, James Mitroka, Narayanan Hariharan, Vinayak Hosagrahara, Gamini Chandrasena, Wen Chyi Shyu, W. Griffith Humphreys	21
20	GLUCURONIDATION AS A MAJOR METABOLIC CLEARANCE PATHWAY OF 14C-LABELED MURAGLITAZAR IN HUMANS: METABOLIC PROFILES IN SUBJECTS WITH OR WITHOUT BILE COLLECTION 2005 ·Drug Metabolism and Disposition ·Lifei Wang, Donglu Zhang, Arun Swaminathan, Yongjun Xue, Peter T. W. Cheng, Shung Wu, Rogelio Mosqueda‐Garcia, (unknown), Donald W. Everett, W. Griffith Humphreys	25

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact